Metformin Increases Bone Marrow Adipose Tissue by Promoting Mesenchymal Stromal Cells Apoptosis

Bone marrow adipose tissue (MAT) has the potential to exert both local and systemic effects on metabolic homeostasis. As a first-line drug used to treat type 2 diabetes mellitus, metformin has conflicting effects on MAT and bone marrow mesenchymal stem cell (BM-MSC) differentiation. Through a series of experiments and , we found that except improving the glucose and lipid metabolism disorder in / mice, 200 mg/kg metformin increased MAT in mice tibia, and prompted osteogenic genes () and lipogenic genes () expression in mice bone marrow. However, metformin promoted osteogenesis and inhibited lipogenesis of MSC , which is inconsistent with the results . Given MAT being considered the "filler" of the space after the apoptosis of bone marrow stroma, the effect of metformin on MSC apoptosis was examined. We discovered that metformin induces MSC apoptosis and . Therefore, we speculated that the increased MAT in mice tibia may be attributed to the filling of adipose tissue after apoptosis of bone marrow stromal cells induced by metformin. The increased MAT may be involved in the regulation of metformin on glucose, lipid, and bone metabolism in diabetic mice, providing a new way to understand the metabolic regulation of metformin. While increased MAT-associated insulin resistance and metabolic disorders may account for the poorer clinical benefits in patients with intensive glucose control.